Compare LPA & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPA | WHWK |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 95.2M |
| IPO Year | N/A | N/A |
| Metric | LPA | WHWK |
|---|---|---|
| Price | $2.75 | $2.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.6K | ★ 186.0K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $47,536,343.00 | $14,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.86 | ★ N/A |
| Revenue Growth | ★ 7.28 | N/A |
| 52 Week Low | $2.55 | $1.39 |
| 52 Week High | $11.47 | $3.81 |
| Indicator | LPA | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 52.76 |
| Support Level | $2.86 | $2.24 |
| Resistance Level | $3.15 | $2.63 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 54.42 |
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.